HF
MLYS icon

HRT Financial’s Mineralys Therapeutics MLYS Stock Holding History

HRT Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$1.81M – 4370
2025
Q4 		$1.81M Buy
+50,000
New +$2.01M 0.01% 1372

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

HRT Financial's MLYS Position: Q1 2026 in Review

HRT Financial increased its Mineralys Therapeutics (MLYS) stake by 158% in Q1 2026, buying an estimated $1.72M and bringing the position to 95,920 shares worth $2.6M. The position accounts for 0.01% of the portfolio, ranked #1432.

HRT Financial first reported a position in MLYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.08M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • HRT Financial held 95,920 shares of Mineralys Therapeutics worth $2.6M as of Q1 2026.
  • HRT Financial bought 58,684 Mineralys Therapeutics shares in Q1 2026, an estimated $1.72M.
  • Mineralys Therapeutics made up 0.01% of HRT Financial's portfolio in Q1 2026, its #1432 holding.
  • HRT Financial first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • HRT Financial's Mineralys Therapeutics position peaked at $5.08M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.